Preferred Label : Recombinant Human Papillomavirus Bivalent Vaccine;
NCIt synonyms : Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant; Recombinant HPV Bivalent Vaccine; Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine; Human Papillomavirus 16 18 L1 Virus-Like Particle AS04 Vaccine; Human Papillomavirus Vaccine L1 16,18; Human Papillomavirus Vaccine, L1 Type 16, 18; HPV-16/18 VLP/AS04 Vaccine;
NCIt related terms : Cervarix; HPV 16/18 L1 VLP/AS04 VAC; GSK-580299;
NCIt definition : A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like
particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective
and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4
vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens,
thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition,
this agent may stimulate an antitumoral cellular immune response against cervical
cancer associated with HPV infection.;
Alternative definition : NCI-GLOSS: A vaccine used to prevent cervical cancer caused by human papillomaviruses
(HPV) types 16 and 18. It is also used to prevent lesions that are caused by these
viruses and that can lead to cervical, vulvar, or vaginal cancer. Cervarix is used
in females aged 10-25 years. It is also being studied in the treatment of other medical
conditions. It is a type of bivalent vaccine.;
Drug name : Cervarix;
Codes from synonyms : CDR0000658364; CDR0000658365; CDR0000658366; CDR0000658367;
Origin ID : C48395;
UMLS CUI : C1721788;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
